1. Home
  2. AXG vs ANL Comparison

AXG vs ANL Comparison

Compare AXG & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AXG

Solowin Holdings Class A Ordinary Share

N/A

Current Price

$3.55

Market Cap

712.4M

Sector

Finance

ML Signal

N/A

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$11.85

Market Cap

731.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
AXG
ANL
Founded
2021
2004
Country
Hong Kong
United States
Employees
33
N/A
Industry
Investment Bankers/Brokers/Service
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
712.4M
731.6M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
AXG
ANL
Price
$3.55
$11.85
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$20.00
AVG Volume (30 Days)
115.3K
306.1K
Earning Date
01-09-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$28.53
$36.02
Revenue Next Year
$54.60
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.69
$0.88
52 Week High
$4.75
$17.25

Technical Indicators

Market Signals
Indicator
AXG
ANL
Relative Strength Index (RSI) 41.96 45.14
Support Level $3.49 $6.92
Resistance Level $3.94 $12.09
Average True Range (ATR) 0.11 1.34
MACD -0.02 -0.44
Stochastic Oscillator 10.34 27.73

Price Performance

Historical Comparison
AXG
ANL

About AXG Solowin Holdings Class A Ordinary Share

Solowin Holdings Ltd is an investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secure one-stop electronic platform. It is engaged in providing securities-related services, investment advisory services, and asset management services to customers. The operations were organized into four reportable segments: Corporate Finance Services, Wealth Management Services, Asset Management Services and Virtual Assets. It derives maximum revenue from Wealth Management Services.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: